The ENABLE research consortium has been awarded a generous €4 million grant from Horizon Europe to combat non-communicable diseases (NCDs) in Ethiopia.
The ENABLE consortium, a collaboration between the Norwegian Institute of Public Health (NIPH) and the Ethiopian Public Health Institute (EPHI), will kick off its mission in 2024 for a period of 4 years.
The project aims to establish a program, using evidence-based interventions, to promote healthy eating habits, increase physical activity, and reduce exposure to pollution within urban communities in Ethiopia.
This initiative will be delivered across four Ethiopian cities: Addis Ababa, Adama, Harar, and Jimma, targeting pregnant women and their children in particular.
This is a prime example of how combining public health, healthcare access, and environmental health, supported by digital tools, can significantly improve a population’s health.
This project aligns with Ethiopia’s National NCD prevention strategy and contributes to closing the global knowledge gap for implementing evidence-based interventions.
The team is led by Dr Eleni Papadopoulou (NIPH) and Dr Masresha Tessema (EPHI) as they embark on this vital mission.
🚀 Understand the market dynamics of Novo Nordisk’s GLP-1 Market Share Decline.
A case of demand underestimation, supply chain strain, and competitor agility. Using systems thinking, we unpack the dynamic forces behind Eli Lilly’s surge—and what strategic levers pharma leaders must pull to stay ahead.
#SyenzaNews #PharmaStrategy #MarketDynamics #NovoNordisk #EliLilly #GLP1
💡 Can tolebrutinib reshape the treatment landscape for progressive multiple sclerosis?
A recent report from the Institute for Clinical and Economic Review reveals promising insights on tolebrutinib, demonstrating a 31% reduction in disability progression for patients with non-relapsing secondary progressive MS. Yet, mixed outcomes and potential safety concerns raise critical questions about its long-term efficacy and market access.
Explore the nuances of this groundbreaking therapy and its implications for healthcare economics.
#SyenzaNews #HealthEconomics #MarketAccess
🌟 What does the EMA’s orphan drug designation for allopurinol mean for those impacted by Marfan syndrome?
This groundbreaking move highlights a significant step forward in tackling rare diseases, offering hope to patients with limited treatment options. Allopurinol, traditionally used for gout, shows promise in addressing life-threatening aortic complications associated with Marfan syndrome, thanks to its antioxidant properties.
Dive into the implications of this development for healthcare innovation, patient access, and the future of rare disease treatment!
#SyenzaNews #HealthEconomics #Innovation #MarketAccess
SPEAK WITH US
CORRESPONDENCE ADDRESS
1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA
WRITE US
JOIN NEWSLETTER
